Assetmark, Inc Chemo Centryx, Inc. Transaction History

Assetmark, Inc

$34.9 Billion
Q3 2024

Shares

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 01, 2022	SELL	$22.17 - $51.8 $7,271 - $16,990	-328 Reduced 18.64%	1,432 $74,000
Q2 2022 Aug 03, 2022	BUY	$15.36 - $27.51 $21,166 - $37,908	1,378 Added 360.73%	1,760 $44,000
Q1 2022 May 13, 2022	BUY	$22.22 - $39.12 $5,932 - $10,445	267 Added 232.17%	382 $10,000
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $2,113 - $4,657	115 New	115 $4,000
Q2 2021 Aug 16, 2021	SELL	$9.59 - $50.88 $335 - $1,780	-35 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$49.53 - $68.4 $346 - $478	7 Added 25.0%	35 $2,000
Q3 2020 Nov 13, 2020	BUY	$46.35 - $61.69 $92 - $123	2 Added 7.69%	28 $2,000
Q2 2020 Aug 11, 2020	SELL	$38.58 - $65.07 $308 - $520	-8 Reduced 23.53%	26 $1,000
Q1 2020 May 12, 2020	BUY	$32.73 - $50.78 $1,112 - $1,726	34 New	34 $1,000
Q3 2019 Nov 13, 2019	SELL	$6.47 - $8.96 $349 - $483	-54 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$8.31 - $14.85 $132 - $237	16 Added 42.11%	54 $1,000
Q1 2019 May 14, 2019	BUY	$10.01 - $13.89 $380 - $527	38 New	38 $1,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.